Matches in SemOpenAlex for { <https://semopenalex.org/work/W2481928264> ?p ?o ?g. }
- W2481928264 endingPage "175" @default.
- W2481928264 startingPage "169" @default.
- W2481928264 abstract "Objective The Rituximab in ANCA‐Associated Vasculitis (RAVE) trial compared rituximab to cyclophosphamide as induction therapy for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. We undertook the current study to determine whether known single‐nucleotide polymorphisms (SNPs) for Fcγ receptors (FcγR) or cytochrome P450 (CYP) enzymes were associated with the response to treatment with rituximab and cyclophosphamide, respectively. Methods Functional SNPs for FcγR (FcγRIIa 519G>A, FcγRIIb 695T>C, FcγRIIIa 559T>G) and CYP enzymes (CYP2B6 1459C>T, CYP2C19 681G>A) were analyzed by direct sequencing of polymerase chain reaction–amplified genomic DNA. Each SNP was tested as a predictor of complete remission at 6 months or remission with continued prednisone administration using logistic regression and including the covariates of baseline Birmingham Vasculitis Activity Score for Wegener's Granulomatosis, ANCA type, and new versus relapsing disease. The associations of these SNPs with the secondary outcomes of time to complete remission, time to relapse, or time to B cell reconstitution were analyzed by Cox proportional hazard tests. Results No significant associations were identified between complete remission and any FcγR genotype in the rituximab group or any CYP genotype in the cyclophosphamide group. However, when the treatment groups were combined, an association was found between the 519AA genotype of FcγRIIa and complete remission ( P = 0.01). The 519AA genotype predicted complete remission ( P = 0.006) and a shorter time to complete remission ( P < 0.001). Conclusion The finding that the homozygous FcγRIIa 519AA variant was associated with complete response and a shorter time to complete response in the RAVE trial, independent of treatment type, implies that FcγRIIa may be broadly involved in disease pathogenesis and response to therapy." @default.
- W2481928264 created "2016-08-23" @default.
- W2481928264 creator A5003454294 @default.
- W2481928264 creator A5004355994 @default.
- W2481928264 creator A5009451090 @default.
- W2481928264 creator A5012718828 @default.
- W2481928264 creator A5012967877 @default.
- W2481928264 creator A5013156684 @default.
- W2481928264 creator A5016851450 @default.
- W2481928264 creator A5025570182 @default.
- W2481928264 creator A5037578600 @default.
- W2481928264 creator A5041400870 @default.
- W2481928264 creator A5042356850 @default.
- W2481928264 creator A5042482253 @default.
- W2481928264 creator A5049800810 @default.
- W2481928264 creator A5051953810 @default.
- W2481928264 creator A5078373797 @default.
- W2481928264 creator A5081516692 @default.
- W2481928264 creator A5081992519 @default.
- W2481928264 creator A5082909035 @default.
- W2481928264 date "2016-12-28" @default.
- W2481928264 modified "2023-09-27" @default.
- W2481928264 title "The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis" @default.
- W2481928264 cites W1544994607 @default.
- W2481928264 cites W1817930542 @default.
- W2481928264 cites W1964824588 @default.
- W2481928264 cites W1967581879 @default.
- W2481928264 cites W1973346712 @default.
- W2481928264 cites W1987135399 @default.
- W2481928264 cites W1991656907 @default.
- W2481928264 cites W199559419 @default.
- W2481928264 cites W1997366448 @default.
- W2481928264 cites W1999520120 @default.
- W2481928264 cites W2010329820 @default.
- W2481928264 cites W2026900314 @default.
- W2481928264 cites W2030371995 @default.
- W2481928264 cites W2031517139 @default.
- W2481928264 cites W2039907938 @default.
- W2481928264 cites W2041222796 @default.
- W2481928264 cites W2044360617 @default.
- W2481928264 cites W2045072103 @default.
- W2481928264 cites W2057745345 @default.
- W2481928264 cites W2063340779 @default.
- W2481928264 cites W2065757905 @default.
- W2481928264 cites W2072441191 @default.
- W2481928264 cites W2072577743 @default.
- W2481928264 cites W2076316204 @default.
- W2481928264 cites W2076489368 @default.
- W2481928264 cites W2082635925 @default.
- W2481928264 cites W2099704507 @default.
- W2481928264 cites W2101185541 @default.
- W2481928264 cites W2108534893 @default.
- W2481928264 cites W2113963745 @default.
- W2481928264 cites W2114346603 @default.
- W2481928264 cites W2116661011 @default.
- W2481928264 cites W2125057361 @default.
- W2481928264 cites W2160264356 @default.
- W2481928264 cites W2171643265 @default.
- W2481928264 cites W2171777347 @default.
- W2481928264 cites W2332793764 @default.
- W2481928264 doi "https://doi.org/10.1002/art.39822" @default.
- W2481928264 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27482943" @default.
- W2481928264 hasPublicationYear "2016" @default.
- W2481928264 type Work @default.
- W2481928264 sameAs 2481928264 @default.
- W2481928264 citedByCount "20" @default.
- W2481928264 countsByYear W24819282642017 @default.
- W2481928264 countsByYear W24819282642018 @default.
- W2481928264 countsByYear W24819282642019 @default.
- W2481928264 countsByYear W24819282642020 @default.
- W2481928264 countsByYear W24819282642021 @default.
- W2481928264 countsByYear W24819282642022 @default.
- W2481928264 countsByYear W24819282642023 @default.
- W2481928264 crossrefType "journal-article" @default.
- W2481928264 hasAuthorship W2481928264A5003454294 @default.
- W2481928264 hasAuthorship W2481928264A5004355994 @default.
- W2481928264 hasAuthorship W2481928264A5009451090 @default.
- W2481928264 hasAuthorship W2481928264A5012718828 @default.
- W2481928264 hasAuthorship W2481928264A5012967877 @default.
- W2481928264 hasAuthorship W2481928264A5013156684 @default.
- W2481928264 hasAuthorship W2481928264A5016851450 @default.
- W2481928264 hasAuthorship W2481928264A5025570182 @default.
- W2481928264 hasAuthorship W2481928264A5037578600 @default.
- W2481928264 hasAuthorship W2481928264A5041400870 @default.
- W2481928264 hasAuthorship W2481928264A5042356850 @default.
- W2481928264 hasAuthorship W2481928264A5042482253 @default.
- W2481928264 hasAuthorship W2481928264A5049800810 @default.
- W2481928264 hasAuthorship W2481928264A5051953810 @default.
- W2481928264 hasAuthorship W2481928264A5078373797 @default.
- W2481928264 hasAuthorship W2481928264A5081516692 @default.
- W2481928264 hasAuthorship W2481928264A5081992519 @default.
- W2481928264 hasAuthorship W2481928264A5082909035 @default.
- W2481928264 hasConcept C104317684 @default.
- W2481928264 hasConcept C126322002 @default.
- W2481928264 hasConcept C135763542 @default.
- W2481928264 hasConcept C143998085 @default.
- W2481928264 hasConcept C153209595 @default.
- W2481928264 hasConcept C159654299 @default.